However, Trastuzumab cytotoxicity by CMC could not be documented experimentally [7], possibly because of the presence of membrane-bound complement regulatory proteins (mCRP) such as decay accelerating factor (DAF; CD55), membrane cofactor protein (MCP; CD46), or protectin (CD59) on the surface of breast carcinoma cells. The gene discussed is CD55; the disease is breast carcinoma.